Background
Methods
Computational analyses of the human genome
Patients and tumor tissues
PCR-based microsatellite analysis
DNA modification by sodium bisulfite
Semiquantitative methylation analysis
Gene symbol | Synonym | Gene description | Accession no. |
---|---|---|---|
CpG islands | |||
CDH1
|
E-CADHERIN
| Cadherin 1, type 1, E-cadherin (epithelial) | NM_004360 |
RABGEF1
|
AJ250042
| RAB guanine nucleotide exchange factor (GEF) 1 | NM_014504 |
STAG1
|
SA1
| Stromal antigen 1 | NM_005862 |
MYBPC2
|
AJ250042
| Myosin binding protein C, fast type | NM_004533 |
VDR
|
J03258
| Vitamin D (1,25- dihydroxyvitamin D3) receptor | NM_000376 |
ESR2
|
AF051428
| Estrogen receptor 2 (ER beta) | NM_001437 |
MLH1
|
HMLH1
| MutL homolog 1, colon cancer, nonpolyposis type 2 | NM_000249 |
FLJ43855
|
AK125843
| similar to sodium- and chloride-dependent creatine transporter | NM_198857 |
PTEN
|
BZS
| Phosphatase and tensin homolog | NM_000314 |
CDKN2A
|
P16
| Cyclin-dependent kinase inhibitor 2A | NM_000077 |
PAX5
|
AY463952
| Paired box gene 5 (B-cell lineage specific activator) | NM_016734 |
RUNX2
|
CBFA1
| Runt-related transcription factor 2 | NM_004348 |
RUNX3
|
CBFA3
| Runt-related transcription factor 3 | NM_004350 |
KIAA1752
| Homo sapiens mRNA for KIAA1752 protein | AB051539* | |
MUC8
| Mucin 8, tracheobronchial | U14383* | |
Non-island CpGs | |||
MAGEA2
|
MAGE-A2
| Melanoma antigen family A, 2 | NM_005361 |
DDX53
|
CAGE
| DEAD (Asp-Glu-Ala-Asp) box polypeptide 53 | NM_182699 |
TFF2
|
SML1
| Trefoil factor 2 (spasmolytic protein 1) | NM_005423 |
SERPINB5
|
MASPIN
| Serpin peptidase inhibitor, clade B (ovalbumin), member 5 | NM_002639 |
MSLN
|
MPF
| Mesothelin isoform 2 precursor | NM_013404 |
Primer position* | Intensity ratio† | ||||||||
---|---|---|---|---|---|---|---|---|---|
Gene | Chromosome locus | CpG sites (kb)* | CpG ratio | GC% | U | M | U | U/M‡ | M |
CDH1
| 16q22 | 0 | 0.73 | 70 | -78 | -76 | 0.92 | 0.49/0.51 | 0.94 |
RABGEF1
| 7q11 | -0.2 | 1.00 | 67 | -285 | -283 | 0.9 | 0.46/0.54 | 0.91 |
STAG1
| 3q22 | -0.4 | 0.95 | 62 | -493 | -490 | 0.93 | 0.51/0.49 | 0.91 |
MYBPC2
| 19q13 | -1.2 | 0.61 | 61 | -1,226 | -1,224 | 0.92 | 0.48/0.52 | 0.94 |
-0.6 | 0.83 | 67 | -742 | -742 | 0.9 | 0.51/0.49 | 0.88 | ||
VDR
| 12q13 | -0.7 | 0.71 | 58 | -728 | -727 | 0.92 | 0.51/0.49 | 0.92 |
+0.1 | 0.84 | 63 | +45 | +45 | 0.95 | 0.51/0.49 | 0.94 | ||
ESR2
| 14q23 | -0.9 | 0.66 | 59 | -983 | -986 | 0.85 | 0.48/0.52 | 0.91 |
MLH1
| 3p22 | -1.0 | 0.43 | 49 | -1,098 | -1,098 | 0.93 | 0.51/0.49 | 0.95 |
-0.6 | 0.85 | 63 | -660 | -655 | 0.94 | 0.48/0.52 | 0.93 | ||
FLJ43855
| 16p11 | -1.1 | 0.62 | 55 | -1147 | -1147 | 0.89 | 0.48/0.52 | 0.90 |
PTEN
| 10q23 | -1.4 | 0.66 | 62 | -1,425 | -1,425 | 0.93 | 0.52/0.48 | 0.91 |
-0.9 | 0.86 | 62 | -953 | -953 | 0.94 | 0.51/0.49 | 0.93 | ||
CDKN2A
| 9p21 | -1.5 | 0.77 | 65 | -1,580 | -1,575 | 0.9 | 0.47/0.53 | 0.93 |
0 | 1.10 | 65 | -85 | -85 | 0.91 | 0.47/0.53 | 0.91 | ||
+0.8 | 0.48 | 51 | 776 | 775 | 0.93 | 0.51/0.49 | 0.96 | ||
PAX5
| 9p13 | -1.0 | 0.50 | 63 | -1,056 | -1,054 | 0.92 | 0.52/0.48 | 0.90 |
RUNX2
| 6p21 | -3.8 | 0.25 | 36 | -3,883 | -3,883 | 0.9 | 0.48/0.52 | 0.93 |
-3.0 | 0.71 | 55 | -3,061 | -3,061 | 0.91 | 0.49/0.51 | 0.92 | ||
-0.7 | 0.81 | 62 | -852 | -850 | 0.93 | 0.52/0.48 | 0.92 | ||
+1.6 | 0.63 | 53 | 1573 | 1573 | 0.92 | 0.47/0.53 | 0.94 | ||
RUNX3
| 1p36 | -1.7 | 0.82 | 60 | -1,790 | -1,790 | 0.89 | 0.46/0.54 | 0.9 |
-0.5 | 0.94 | 75 | -559 | -559 | 0.91 | 0.48/0.52 | 0.9 | ||
-0.1 | 1.07 | 76 | -219 | -217 | 0.92 | 0.5/0.5 | 0.93 | ||
+1.0 | 0.79 | 59 | 952 | 952 | 0.91 | 0.49/0.51 | 0.93 | ||
KIAA1752
| 16q12 | +0.4 | 0.42 | 41 | 391 | 391 | 0.92 | 0.48/0.52 | 0.94 |
MUC8
| 12q24 | +2.0 | 0.42 | 59 | 1,909 | 1,909 | 0.94 | 0.49/0.51 | 0.95 |
MAGEA2
| Xq28 | 0 | 0.56 | 64 | -81 | -75 | 0.9 | 0.54/0.46 | 0.91 |
DDX53
| Xq22.11 | 0 | 0.53 | 59 | -71 | -102 | 0.94 | 0.48/0.52 | 0.94 |
TFF2
| 21q22 | -0.2 | 0.32 | 57 | -251 | -251 | 0.96 | 0.5/0.5 | 0.96 |
SERPINB5
| 18q21 | -0.3 | 0.62 | 51 | -315 | -308 | 0.93 | 0.51/0.49 | 0.94 |
MSLN
| 16q13 | -0.8 | 0.52 | 57 | -827 | -827 | 0.92 | 0.47/0.53 | 0.93 |
Methylation-specific PCR | |||||
---|---|---|---|---|---|
CpG sites* | Case no. | 32-cycle amplicons using radioisope | 37-cycle amplicons using ethidium bromide | % Methylation in 10 common PCR clones | |
MYBPC2, -1.2 kb | 1 | Normal | Level 4 | Level 4 | 53/70‡ (76%) |
Tumor | Level 4 | Level 4 | 48/70 (69%) | ||
26 | Normal | Level 4 | Level 4 | 47/70 (67%) | |
Tumor | Level 3 | No band | 32/70 (46%) | ||
VDR, -0.7 kb | 1 | Normal | Level 1 | Level 1 | 4/130 (3%) |
Tumor | Level 1 | Level 1 | 12/130 (9%) | ||
26 | Normal | Level 2 | Level 2 | 44/130 (34%) | |
Tumor | Level 3 | Level 3 | 64/130 (49%) | ||
MLH1, -1.0 kb | 1 | Normal | Level 3 | Level 3 | 14/30 (47%) |
Tumor | Level 2 | Level 3† | 10/30 (33%) | ||
26 | Normal | Level 2 | No band | 9/30 (30%) | |
Tumor | Level 4† | Level 3 | 17/30 (57%) | ||
MLH1, -0.6 kb | 1 | Normal | Level 1 | Level 1 | 0/200 (0%) |
Tumor | Level 1 | Level 1 | 0/200 (0%) | ||
26 | Normal | Level 1 | Level 1 | 4/200 (2%) | |
Tumor | Level 1 | Level 1 | 4/200 (2%) | ||
CDKN2A, -1.5 kb | 1 | Normal | Level 2 | Level 2 | 19/60 (32%) |
Tumor | Level 1 | Level 1 | 5/60 (8%) | ||
26 | Normal | Level 2 | Level 2 | 13/60 (22%) | |
Tumor | Level 5 | No band | 54/60 (90%) | ||
CDKN2A, 0 kb | 1 | Normal | Level 1 | Level 1 | 0/110 (0%) |
Tumor | Level 1 | Level 1 | 0/110 (0%) | ||
26 | Normal | Level 1 | Level 1 | 0/110 (0%) | |
Tumor | Level 4 | Level 3† | 76/110 (69%) | ||
RUNX2, -3.0 kb | 1 | Normal | Level 1 | Level 1 | 8/60 (13%) |
Tumor | Level 1 | Level 1 | 8/60 (13%) | ||
26 | Normal | Level 2† | No band | 11/60 (18%) | |
Tumor | Level 2† | Level 1 | 9/60 (15%) | ||
RUNX3, -1.7 kb | 1 | Normal | Level 1 | Level 1 | 6/70 (10%) |
Tumor | Level 3 | Level 3 | 38/70 (54%) | ||
26 | Normal | Level 2 | Level 3† | 27/70 (39%) | |
Tumor | Level 4 | Level 3† | 45/70 (64%) | ||
MAGEA2, 0 kb | 1 | Normal | Level 5 | Level 5 | 106/110 (96%) |
Tumor | Level 2 | Level 2 | 41/110 (37%) | ||
26 | Normal | Level 5 | Level 5 | 104/110 (95%) | |
Tumor | Level 5 | Level 5 | 103/110 (94%) | ||
TFF2, -0.2 kb | 1 | Normal | Level 2 | Level 3† | 21/60 (35%) |
Tumor | Level 2 | Level 3† | 19/60 (32%) | ||
26 | Normal | Level 3 | Level 3 | 32/60 (53%) | |
Tumor | Level 2† | Level 3 | 25/60 (42%) | ||
SERPINB5, -0.3 kb | 1 | Normal | Level 3 | Level 3 | 36/70 (51%) |
Tumor | Level 2† | No band | 31/70 (44%) | ||
26 | Normal | Level 2 | Level 3† | 26/70 (37%) | |
Tumor | Level 2 | No band | 27/70 (39%) | ||
MSLN, -0.8 kb | 1 | Normal | Level 5 | Level 5 | 66/70 (94%) |
Tumor | Level 3 | Level 4† | 38/70 (54%) | ||
26 | Normal | Level 4 | Level 4 | 51/70 (73%) | |
Tumor | Level 5 | Level 5 | 61/70 (87%) |
Statistical analysis
Results
Analysis of the transitional area between the CpG Islands and the nearest retroelements
Genetic classification of gastric cancers according to the level of LOHs
Total | High LOH | Low LOH | p† | Baseline LOH | Microsatellite instability | |
---|---|---|---|---|---|---|
No. of patients | 50 | 20 | 19 | 6 | 5 | |
Age (years) | ||||||
Mean ± SD | 59.6 ± 12.6 | 60.5 ± 11.7 | 61.1 ± 11.6 | 0.883 | 55.0 ± 7.9 | 66.8 ± 7.3 |
Tumor size (cm) | ||||||
Mean ± SD | 4.9 ± 2.8 | 5.2 ± 2.7 | 4.4 ± 3.1 | 0.402 | 4.3 ± 1.8 | 6.3 ± 3.2 |
Sex | ||||||
Male | 32 | 15 | 12 | 0.325 | 3 | 2 |
Female | 18 | 5 | 7 | 3 | 3 | |
Lauren classification | ||||||
Intestinal | 29 | 10 | 16 | 0.032 | 0 | 3 |
Diffuse | 11 | 5 | 3 | 3 | 0 | |
Mixed | 10 | 5 | 0 | 3 | 2 | |
Differentiation | ||||||
Well | 4 | 0 | 3 | 0.046 | 0 | 1 |
Moderate | 26 | 11 | 13 | 0 | 2 | |
Poor | 20 | 9 | 3 | 6 | 2 | |
Growth pattern | ||||||
Infiltrative | 27 | 14 | 9 | 0.126 | 2 | 2 |
Expanding | 3 | 0 | 3 | 0 | 0 | |
Mixed | 20 | 6 | 7 | 4 | 3 | |
Venous invasion | ||||||
Yes | 6 | 4 | 0 | 0.059 | 2 | 0 |
No | 44 | 16 | 19 | 4 | 5 | |
Lymphatic invasion | ||||||
Yes | 29 | 16 | 5 | 0.001 | 5 | 3 |
No | 21 | 4 | 14 | 1 | 2 | |
Tumor stage | ||||||
Early stage | 29 | 8 | 15 | 0.015 | 2 | 4 |
Advanced stage | 21 | 12 | 4 | 4 | 1 |
Relationships between the LOHs and methylation alterations
High-level chromosomal loss (n = 20) | Low-level chromosomal loss (n = 19) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Mean level of methylation | Methylation alterations (%) | Mean level of methylation | Methylation alterations (%) | |||||||
CpG sites* | Normal | Tumor | p† | Hypo- | Hyper- | Normal | Tumor | p† | Hypo- | Hyper- |
CpG islands | ||||||||||
CDH1, 0 kb | 1.2 | 1.0 | 0.083 | 3 (15) | 0 (0) | 1.1 | 1.1 | 0.560 | 0 (0) | 1 (5) |
RABGEF1, -0.2 kb | 1.1 | 1.0 | 0.163 | 2 (10) | 0 (0) | 1.0 | 1.0 | 1 | 0 (0) | 0 (0) |
STAG1, -0.4 kb | 1.1 | 1.0 | 0.330 | 1 (5) | 0 (0) | 1.0 | 1.0 | 1 | 0 (0) | 0 (0) |
MYBPC2, -0.6 kb | 1.6 | 1.6 | 0.757 | 2 (10) | 1 (5) | 2.0 | 2.3 | 0.090 | 0 (0) | 4 (21) |
MLH1, -0.6 kb | 1.4 | 1.4 | 1 | 5 (25) | 2 (10) | 1.3 | 1.7 | 0.153 | 0 (0) | 4 (21) |
PTEN, -0.9 kb | 1.3 | 1.2 | 0.442 | 2 (10) | 0 (0) | 1.1 | 1.1 | 0.560 | 1 (5) | 2 (11) |
CDKN2A, 0kb | 1.1 | 1.0 | 0.330 | 1 (5) | 0 (0) | 1.0 | 1.4 | 0.072 | 0 (0) | 4 (21) |
PAX5, -1.0 kb | 2.0 | 1.7 | 0.115 | 7 (35) | 0 (0) | 1.9 | 2.1 | 0.505 | 4 (21) | 5 (26) |
RUNX2, -3.8 kb | 4.2 | 3.8 | 0.054 | 7 (35) | 0 (0) | 4.2 | 4.3 | 0.376 | 1 (5) | 4 (21) |
-3.0 kb | 1.8 | 1.8 | 1 | 5 (25) | 5 (25) | 2.0 | 2.0 | 1 | 3 (16) | 4 (21) |
-0.7 kb | 2.1 | 2.0 | 0.575 | 5 (25) | 4 (20) | 1.7 | 1.9 | 0.266 | 4 (21) | 6 (32) |
+1.6 kb | 2.0 | 2.2 | 0.295 | 3 (15) | 5 (25) | 2.1 | 2.5 | 0.066 | 2 (11) | 7 (37) |
RUNX3, -1.7 kb | 2.0 | 3.3 | <0.0001 | 0 (0) | 14 (70) | 2.5 | 3.3 | 0.012 | 0 (0) | 12 (63) |
-0.5 kb | 1.3 | 1.1 | 0.121 | 6 (30) | 2 (10) | 1.8 | 2.4 | 0.035 | 2 (11) | 9 (47) |
-0.1 kb | 1.2 | 1.0 | 0.042 | 4 (20) | 0 (0) | 1.0 | 1.2 | 0.042 | 0 (0) | 4 (21) |
+1.0 kb | 4.0 | 3.8 | 0.519 | 6 (30) | 5 (25) | 3.4 | 3.8 | 0.012 | 0 (0) | 7 (37) |
VDR, +0.1 kb | 1.0 | 1.0 | 1 | 0 (0) | 0 (0) | 1.0 | 1.0 | 1 | 0 (0) | 0 (0) |
KIAA1752, +0.4 kb | 2.8 | 2.6 | 0.096 | 8 (40) | 0 (0) | 2.1 | 2.5 | 0.084 | 0 (0) | 7 (37) |
Transitional CpGs | ||||||||||
MYBPC2, -1.2 kb | 4.3 | 4.1 | 0.083 | 4 (20) | 0 (0) | 4.3 | 4.2 | 0.546 | 5 (26) | 2 (11) |
VDR, -0.7 kb | 1.8 | 1.3 | 0.003 | 10 (50) | 0 (0) | 1.5 | 2.1 | 0.056 | 3 (16) | 8 (42) |
ESR2, -0.9 kb | 1.7 | 1.4 | 0.114 | 6 (30) | 0 (0) | 1.3 | 1.5 | 0.141 | 0 (0) | 4 (22) |
MLH1, -1.0 kb | 3.1 | 2.5 | 0.050 | 9 (45) | 2 (10) | 2.8 | 3.5 | 0.035 | 1 (5) | 11 (58) |
FLJ43855, -1.1 kb | 4.0 | 3.5 | 0.043 | 10 (50) | 2 (10) | 3.7 | 4.1 | 0.072 | 2 (11) | 8 (42) |
PTEN, -1.4 kb | 1.4 | 1.1 | 0.062 | 5 (25) | 0 (0) | 1.1 | 1.3 | 0.119 | 1 (5) | 5 (26) |
CDKN2A, -1.5 kb | 2.0 | 1.6 | 0.012 | 10 (50) | 2 (10) | 2.0 | 2.8 | 0.025 | 3 (16) | 10 (53) |
+0.8 kb | 4.4 | 3.6 | 0.002 | 12 (60) | 0 (0) | 4.1 | 4.4 | 0.173 | 3 (16) | 7 (37) |
MUC8, +2.0 kb | 4.4 | 3.7 | 0.001 | 9 (45) | 0 (0) | 4.4 | 4.2 | 0.149 | 6 (32) | 2 (11) |
MAGEA2, 0 kb | 4.8 | 3.4 | <0.0001 | 11 (55) | 0 (0) | 4.8 | 4.6 | 0.336 | 2 (11) | 0 (0) |
DDX53, 0 kb | 4.2 | 3.7 | 0.051 | 9 (45) | 2 (10) | 4.5 | 3.9 | 0.096 | 6 (32) | 2 (11) |
TFF2, -0.2 kb | 2.4 | 2.1 | 0.174 | 7 (35) | 2 (10) | 2.2 | 2.0 | 0.324 | 6 (32) | 2 (11) |
SERPINB5, -0.3 kb | 2.7 | 2.2 | 0.080 | 10 (50) | 3 (15) | 2.4 | 2.5 | 0.598 | 2 (11) | 4 (21) |
MSLN, -0.8 kb | 4.3 | 3.6 | 0.005 | 11 (55) | 2 (10) | 3.5 | 3.7 | 0.591 | 1 (5) | 5 (26) |
Relationships between methylation alterations and the clinicopathological features
Mean frequency of methylation alterations* (%, mean ± SD) | |||||
---|---|---|---|---|---|
Clinicopathological variables | No. of patients | Hypomethylation | p† | Hypermethylation | p† |
Age (years) | |||||
≤55 | 7 | 34.7 ± 28.4 | 0.547 | 11.2 ± 9.1 | 0.384 |
>55 | 32 | 29.0 ± 20.1 | 16.5 ± 15.2 | ||
Tumor size (cm) | |||||
≤5 | 24 | 24.7 ± 16.7 | 0.056 | 17.3 ± 15.6 | 0.359 |
> 5 | 15 | 38.6 ± 27.4 | 12.9 ± 12.1 | ||
Sex | |||||
Male | 27 | 28.8 ± 22.2 | 0.619 | 14.5 ± 15.0 | 0.514 |
Female | 12 | 32.7 ± 22.9 | 17.8 ± 13.1 | ||
Lauren classification | |||||
Intestinal | 26 | 28.0 ± 21.3 | 0.727 | 18.1 ± 15.0 | 0.189 |
Diffuse | 8 | 34.8 ± 29.4 | 13.4 ± 12.9 | ||
Mixed | 5 | 32.9 ± 15.6 | 5.7 ± 9.3 | ||
Differentiation | |||||
Well | 3 | 23.8 ± 10.9 | 0.671 | 23.8 ± 8.2 | 0.169 |
Moderate | 24 | 28.6 ± 22.2 | 17.6 ± 15.3 | ||
Poor | 12 | 34.5 ± 24.7 | 9.5 ± 11.9 | ||
Growth pattern | |||||
Infiltrative | 23 | 32.6 ± 25.6 | 0.639 | 13.4 ± 12.9 | 0.221 |
Expanding | 3 | 21.4 ± 14.3 | 28.6 ± 14.3 | ||
Mixed | 13 | 27.4 ± 16.7 | 16.5 ± 16.1 | ||
Venous invasion | |||||
Yes | 4 | 37.5 ± 16.9 | 0.485 | 1.8 ± 3.6 | 0.041 |
No | 35 | 29.2 ± 22.7 | 17.1 ± 14.3 | ||
Lymphatic invasion | |||||
Yes | 21 | 38.8 ± 25.2 | 0.006 | 9.5 ± 10.4 | 0.003 |
No | 18 | 19.8 ± 12.1 | 22.6 ± 15.3 | ||
Tumor stage | |||||
Early stage | 23 | 23.0 ± 15.1 | 0.015 | 19.9 ± 15.7 | 0.023 |
Advanced stage | 16 | 40.2 ± 26.9 | 9.4 ± 9.7 |